{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-24-000029","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.434352+00:00","generated_at":"2026-05-31T11:50:11.186184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data","bullets":["Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.","LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.","Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.","LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.","Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-24-000029","json":"https://secwatch.observer/filing/0001759425-24-000029.json","markdown":"https://secwatch.observer/filing/0001759425-24-000029.md","text":"https://secwatch.observer/filing/0001759425-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/0001759425-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/mirm-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:50:11.186184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}